Granite Point Capital Management, L.P. Salarius Pharmaceuticals, Inc. Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$0.8 - $1.15 $468,327 - $673,220	-585,409 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.02 - $1.52 $997,715 - $1.49 Million	-978,152 Reduced 62.56%	585,409 $621,000
Q1 2021 May 12, 2021	BUY	$1.0 - $3.0 $1.56 Million - $4.69 Million	1,563,561 New	1,563,561 $2.31 Million

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.